Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Primary Pulmonary Alveolar Proteinosis
NCT00552461Phase 2Completed
- Sponsor
- East Carolina University
- Start
- Jan 2007
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in pulmonary alveolar proteinosis (PAP), sponsored by East Carolina University. Primary endpoints: Arterial Oxygen Tension at 6 months, Alveolar-arterial Oxygen Gradient at 6 months and 2 more. Started Jan 2007; status: completed.
02
Drugs
rituximab
03
Conditions
pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on NCT00552461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00552461.